人肺癌组织耐药基因(MDR1)表达及意义  

Clinical Correlation of MDR1 Gene Expression in Human Lung Cancer

作　　者：张志华[1] 张秀珑[1] 高振强[1] 李桂林[1] 张春山[1] 刘昭[1] 

机构地区：[1]张家口医学院一附院

出　　处：《中国慢性病预防与控制》1997年第3期106-109,共4页Chinese Journal of Prevention and Control of Chronic Diseases

摘　　要：应用ＰＣＲ定量分析技术对１０４例肺癌患者的ＭＤＲ１基因进行了前瞻性研究，结果发现，初治患者６９％（５５／８０）有ＭＤＲ１基因表达增高，而经过治疗的患者１００％（２４／２４）有ＭＤＲ１基因表达增高，其中小细胞肺癌（ＳＣＬＣ）的增高有显著意义（Ｐ＜０．０１），在没有经过治疗的患者，２１％（１８／８０）ＭＤＲ１表达量处于高水平，而经过治疗的患者，７５％（１８／２４）ＭＤＲ１表达量较高（Ｐ＜０．０１）。ＭＤＲ１基因高表达的患者化疗有效率明显低于ＭＤＲ１不表达或低表达的患者，其中以ＳＣＬＣ患者最为明显（Ｐ＜０．０１）。结果表明，检测肺癌患者尤其是ＳＣＬＣ患者的ＭＤＲ１基因的表达情况，对临床指导化疗非常重要。non small cell lung cancers(NSCLCs) and 40 small cell lung cancers(SCLCs) patients were measured MDR1 by PCR method in this retrospective study.The levels of MDR1 mRNA were expressed among previously untreated patients in 69% of all cases,80% of NSCLCs,50% of SCLCs.There was 100% of all tumors expressed MDR1 mRNA among pretreated patients and significant different in SCLCs ( P <0 01)。MDR1 expressed was low level among non treated one (21%) 75% for treated group ( P <0 01).That meaning was which MDR1 might be a sensitive item for clinical treatment,especially for SCLCs.

关 键 词：肺肿瘤 耐药基因 肺癌 基因表达 

分 类 号：R734.202[医药卫生—肿瘤]